Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
hepatitis B
Pharma
Gilead's Vemlidy scores pediatric approval for chronic hep B
Gilead's Vemlidy, originally approved back in 2016, scored a new FDA indication to treat patients ages 12 and up with chronic hepatitis B virus.
Zoey Becker
Nov 2, 2022 11:15am
FDA swats away Gilead's hepatitis D treatment bulevirtide
Oct 28, 2022 9:52am
Gilead settles Descovy patent feuds with 5 drugmakers
Sep 12, 2022 10:05am
Gilead trumpets a Biktarvy win in HIV, hepatitis B co-infection
Aug 1, 2022 10:17am
FDA approves VBI's PreHevbrio just as HBV market is set to grow
Dec 1, 2021 10:34am
Efficacy, convenient dosage give Dynavax's Heplisav-B an edge
Nov 5, 2021 7:00am
